Klein, Samuel |
| Completed | 2 | 4 | US | Vigabatrin, sabril | Washington University School of Medicine | NAFLD, Obesity | 12/23 | 05/24 | | |
| Withdrawn | 2 | 48 | US | ADI-PEG20, Placebo | Washington University School of Medicine, Children's Discovery Institute, Polaris Pharmaceuticals, Inc. | Obesity, PreDiabetes | 04/24 | 05/24 | | |
NCT03091725: A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB |
|
|
| Recruiting | N/A | 24 | US | Roux-en-Y gastric bypass surgery, Very low-calorie diet | Washington University School of Medicine, National Center for Advancing Translational Sciences (NCATS) | Obesity | 07/25 | 12/25 | | |
| Active, not recruiting | N/A | 70 | US | Roux-en-Y gastric bypass surgery, Low-calorie diet | Washington University School of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity, Type 2 Diabetes | 04/25 | 04/26 | | |
NCT06218147: Community-Based Nutrition-Lifestyle Therapy for Pregnant Latina Women With Diabetes |
|
|
| Recruiting | N/A | 30 | US | Nutrition-behavior lifestyle program, Plant forward dietary lifestyle intervention | Sansum Diabetes Research Institute | Diabetes Mellitus, Type 2, Diabetes Mel Gestational - in Pregnancy | 12/24 | 12/25 | | |
| Active, not recruiting | N/A | 20 | US | Weight loss | Washington University School of Medicine, Lipedema Foundation | Lipedema, Metabolism | 12/24 | 03/25 | | |
NCT02706262: Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health |
|
|
| Recruiting | N/A | 180 | US | Metabolically abnormal obese - Mediterranean diet, Metabolically abnormal obese - Low carbohydrate ketogenic diet, Metabolically abnormal obese - Plant-based, very-low-fat diet | Washington University School of Medicine, Pershing Square Foundation | Obesity, Insulin Resistance | 07/25 | 12/25 | | |
NCT06503809: Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes |
|
|
| Recruiting | N/A | 58 | US | Ketogenic Diet, Standard Diet | Washington University School of Medicine | Diabetes Mellitus, Type 1 | 03/29 | 12/29 | | |
NCT01104220: Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk |
|
|
| Active, not recruiting | N/A | 144 | US | Weight loss | Washington University School of Medicine, Pfizer | Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity, Obesity | 09/24 | 12/24 | | |
NCT04571008: Effect of NMN Supplementation on Organ System Biology |
|
|
| Active, not recruiting | N/A | 56 | US | Placebo, Treatment | Washington University School of Medicine, United States Department of Defense | Glucose Metabolism Disorders | 02/25 | 09/25 | | |
| Recruiting | N/A | 300 | US | Mediterranean diet, Low-carbohydrate, ketogenic diet, Low-fat diet, Annual follow-up testing for 5 years | Washington University School of Medicine, Centene Corporation | Obesity, Insulin Resistance | 10/29 | 12/29 | | |
Connolly, Anne |
NCT05412394: Once Weekly Infant Corticosteroid Trial for DMD |
|
|
| Recruiting | 4 | 26 | US | Prednisolone, Corticosteroid | Anne M. Connolly, Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital Medical Center, Cincinnati, Muscular Dystrophy Association, University of Texas, Virginia Commonwealth University | Duchenne Muscular Dystrophy | 08/26 | 12/26 | | |
EMERGENE, NCT06246513: A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 |
|
|
| Recruiting | 3 | 15 | Europe, US | SRP-9003, scAAVrh74.MHCK7.hSGCB, bidridistrogene xeboparvovec, Glucocorticoid, Prednisone or equivalent | Sarepta Therapeutics, Inc. | Limb-girdle Muscular Dystrophy | 01/25 | 11/29 | | |
NCT06503367: Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy |
|
|
| Not yet recruiting | N/A | 44 | US | | Nationwide Children's Hospital, National Institute of Neurological Disorders and Stroke (NINDS), Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital Medical Center, Cincinnati, University of Iowa, Washington University School of Medicine, Stanford University, University of Utah, University of Rochester, University of Pittsburgh, University of Texas, Southwestern Medical Center at Dallas, University of Minnesota, UCLA Ronald Reagan Medical Center, Boston Children's Hospital | LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\) | 09/28 | 09/28 | | |
Bateman, Randall |
| Recruiting | 3 | 65 | Europe, US, RoW | lecanemab, BAN2401 | Washington University School of Medicine, Alzheimer's Association, Eisai Inc. | Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial | 11/29 | 11/29 | | |
DIAN-TU, NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation |
|
|
| Terminated | 2/3 | 73 | Europe, US, RoW | Gantenerumab, RO4909832 | Washington University School of Medicine, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA) | Alzheimers Disease, Dementia, Alzheimers Disease, Familial | 10/23 | 11/23 | | |
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation |
|
|
| Active, not recruiting | 2/3 | 197 | Europe, Canada, Japan, US, RoW | E2814, Lecanemab, BAN2401, Matching Placebo (E2814) | Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc. | Alzheimers Disease, Dementia, Alzheimers Disease, Familial | 04/28 | 07/28 | | |
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001 |
|
|
| Recruiting | 2/3 | 490 | Europe, Canada, Japan, US, RoW | Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814) | Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP | Alzheimers Disease, Dementia, Alzheimers Disease, Familial | 04/28 | 07/28 | | |
|
|
|
NCT03938870: CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease |
|
|
| Completed | N/A | 96 | US | L-Leucine 13C6 | Washington University School of Medicine, BrightFocus Foundation, National Institutes of Health (NIH) | Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders, Dementia, Mental Disorders, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies | 07/23 | 07/23 | | |
| Completed | N/A | 1122 | US | Blood collection, PiB PET/MRI, and cognitive testing | Washington University School of Medicine | Alzheimer Disease, Alzheimer Dementia | 01/24 | 01/24 | | |
| Recruiting | N/A | 700 | Europe, Canada, Japan, US, RoW | | Washington University School of Medicine, National Institute on Aging (NIA) | Alzheimer's Disease | 07/25 | 07/25 | | |
| Enrolling by invitation | N/A | 1800 | US | Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments | Washington University School of Medicine, National Institute on Aging (NIA) | Alzheimer Disease, Mild Cognitive Impairment, Dementia | 12/28 | 12/28 | | |
Rudnick, David |
| Recruiting | 2 | 163 | US | High-dose methylprednisolone, Solu-Medrol, Equine anti-thymocyte globulin, ATGAM, Prednisolone, 15 mg/mL oral solution National Drug Code: 62135-250-37, Placebo for prednisolone, Placebo for infusions, 0.9% Sodium chloride, Diphenhydramine, Benadryl, Methylprednisolone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ann & Robert H Lurie Children's Hospital of Chicago | Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation | 01/26 | 01/27 | | |
Politi, Mary C |
| Completed | 3 | 300 | US | Anesthetic technique Propofol TIVA, Propofol TIVA, Anesthetic technique inhaled agent, Inhaled agent | Washington University School of Medicine, University of Michigan, University of Pennsylvania, Stanford University, Patient-Centered Outcomes Research Institute | Surgery--Complications, Anesthesia Complication, Anesthesia Awareness, Anesthesia Emergence Delirium, Anesthesia, Surgery, Quality of Life, Pain, Postoperative, Nausea, Postoperative, Anesthesia Morbidity, Depression, Sleep Disorders, Circadian Rhythm | 04/23 | 06/23 | | |
| Completed | N/A | 396 | US | Breast Reconstruction Education and Support Tool (BREASTChoice), BREASTChoice, Attention Control Website, Clinician Survey | Washington University School of Medicine, Agency for Healthcare Research and Quality (AHRQ) | Breast Reconstruction, Breast Cancer | 07/22 | 02/23 | | |
NCT06340646: Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) |
|
|
| Recruiting | N/A | 990 | US | Return of Genetic Results: Biomarker information from cancer cells, Return of Genetic Results: Inherited mutations related to cancer, Return of Genetic Results: Inherited mutations related to other medical issues | Washington University School of Medicine, National Cancer Institute (NCI), The Foundation for Barnes-Jewish Hospital | Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer | 01/27 | 01/27 | | |
NCT05434598: Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS |
|
|
| Recruiting | N/A | 60 | US | ChromoSeq | Washington University School of Medicine, American Society of Hematology, Edward P. Evans Foundation, National Cancer Institute (NCI) | Whole Genome Sequencing, Myelodysplastic Syndromes | 07/27 | 08/27 | | |
NCT06804837: Implement and Test Visual Consent Template and Process |
|
|
| Not yet recruiting | N/A | 313 | US | Visual consent, Standard consent | Washington University School of Medicine, Agency for Healthcare Research and Quality (AHRQ) | Cancer, Alzheimer Disease | 05/26 | 05/26 | | |
NCT05685511: Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery |
|
|
| Recruiting | N/A | 110 | US | Behavioral Activation, Medication Optimization | Washington University School of Medicine, National Institute of Mental Health (NIMH) | Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy | 05/25 | 05/25 | | |
| Recruiting | N/A | 100 | US | Behavioral activation, Medication optimzation, Care as usual | Washington University School of Medicine, National Institute of Mental Health (NIMH) | Orthopedic Surgery, Older Adults, Depression, Anxiety | 02/26 | 02/26 | | |
NCT04986657: Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS |
|
|
| Recruiting | N/A | 275 | US | ChromoSeq | Washington University School of Medicine | Whole Genome Sequencing, Acute Myeloid Leukemia, Myelodysplastic Syndromes | 12/27 | 12/27 | | |
McNicholas, Colleen |
NCT04558229: RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users |
|
|
| Recruiting | 4 | 348 | US | Additional Standardized Counseling | Planned Parenthood of the St. Louis Region and Southwest Missouri, Merck Sharp & Dohme LLC | Birth Control, Contraception, Contraceptive Usage, Family Planning | 11/24 | 06/25 | | |
Ghoshal, Nupur |
NCT04363684: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) |
|
|
| Recruiting | N/A | 2100 | Canada, US | | Mayo Clinic, University of California, San Francisco, National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS) | Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy | 06/25 | 06/25 | | |
| Active, not recruiting | N/A | 342 | US | | The Bluefield Project to Cure Frontotemporal Dementia, Mayo Clinic, University of California, San Francisco | Frontotemporal Dementia, Frontotemporal Lobar Degeneration, FTD-GRN, FTD, FTLD | 02/27 | 02/27 | | |
Korenblat, Kevin |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) |
|
|
| Active, not recruiting | 2 | 24 | US | zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension | Kezar Life Sciences, Inc. | Autoimmune Hepatitis | 02/25 | 08/25 | | |
NCT00301379: Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients |
|
|
| Terminated | N/A | 59 | US | Observation data collection study. | Washington University School of Medicine | Cholangiocarcinoma | 06/23 | 06/23 | | |
Buck, Jill |
| Recruiting | N/A | 700 | Europe, Canada, Japan, US, RoW | | Washington University School of Medicine, National Institute on Aging (NIA) | Alzheimer's Disease | 07/25 | 07/25 | | |
Sigurdson, Wendy |
NCT03938870: CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease |
|
|
| Completed | N/A | 96 | US | L-Leucine 13C6 | Washington University School of Medicine, BrightFocus Foundation, National Institutes of Health (NIH) | Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders, Dementia, Mental Disorders, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies | 07/23 | 07/23 | | |
| Recruiting | N/A | 700 | Europe, Canada, Japan, US, RoW | | Washington University School of Medicine, National Institute on Aging (NIA) | Alzheimer's Disease | 07/25 | 07/25 | | |
Arb, Teresa |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
| Recruiting | 3 | 50 | Europe, Japan, US, RoW | Iptacopan, LNP023 | Novartis Pharmaceuticals, Novartis Pharma AG | Atypical Hemolytic Uremic Syndrome | 09/28 | 03/29 | | |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
Saenz, Jose Luis Perez |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 1 | 500 | Europe, Japan, US, RoW | LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab | Eli Lilly and Company | Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer | 06/20 | 12/27 | | |
Desaro, Pamela |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/28 | 05/28 | | |
| Recruiting | 2 | 116 | Europe, US | Inebilizumab, UPLIZNA, Placebo | University of Utah | Autoimmune Encephalitis, Encephalitis | 10/25 | 08/26 | | |
Biggs, Loire |
NCT04558229: RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users |
|
|
| Recruiting | 4 | 348 | US | Additional Standardized Counseling | Planned Parenthood of the St. Louis Region and Southwest Missouri, Merck Sharp & Dohme LLC | Birth Control, Contraception, Contraceptive Usage, Family Planning | 11/24 | 06/25 | | |
Li, Tingting |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
| Completed | N/A | 4 | RoW | use wearable devices to monitoring fetal health conditions., Non-invasive monitoring, FECG, EHG | Fudan University | Uterine Contractions; Prolonged, Fetal Heart Rate or Rhythm Abnormality Affecting Fetus, Pregnancy Related, Home Range | 07/23 | 08/23 | | |
Teshome, Mengesha |
| Recruiting | 2 | 116 | Europe, US | Inebilizumab, UPLIZNA, Placebo | University of Utah | Autoimmune Encephalitis, Encephalitis | 10/25 | 08/26 | | |
Winkelmann, Janet |
| Active, not recruiting | N/A | 20 | US | Weight loss | Washington University School of Medicine, Lipedema Foundation | Lipedema, Metabolism | 12/24 | 03/25 | | |
| Recruiting | N/A | 300 | US | Mediterranean diet, Low-carbohydrate, ketogenic diet, Low-fat diet, Annual follow-up testing for 5 years | Washington University School of Medicine, Centene Corporation | Obesity, Insulin Resistance | 10/29 | 12/29 | | |
Hartman, Hannah |
CEDAR, NCT04819841: Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease |
|
|
| Recruiting | 1/2 | 15 | US | nula-cel Drug Product | Kamau Therapeutics | Sickle Cell Disease | 07/26 | 07/27 | | |
| Recruiting | 1/2 | 413 | Europe, Canada, US, RoW | revumenib, SNDX-5613, cobicistat | Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | 12/27 | 12/27 | | |
|
|
|
|
|
|
|
|
|
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
|
|
| Active, not recruiting | 1/2 | 153 | NA | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 05/25 | 05/25 | | |
|
Krings, James G |
NCT05689983: Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers |
|
|
| Recruiting | 1/2 | 40 | US | Maintenance ICS and Symptom Driven SABA, Symptom-driven budesonide/formoterol combination | Washington University School of Medicine, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS) | Asthma in Children, Nonadherence, Medication | 12/24 | 12/24 | | |
NCT05111262: Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers |
|
|
| Recruiting | 1/2 | 60 | US | Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA | Washington University School of Medicine, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS) | Asthma, Nonadherence, Medication | 01/25 | 01/25 | | |
Laurido-Soto, Osvaldo |
VNS-AIS, NCT05390580: Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct |
|
|
| Recruiting | N/A | 80 | US | transcutaneous auricular vagal nerve stimulation, Sham transcutaneous vagal nerve stimulation | Washington University School of Medicine | Acute Ischemic Stroke | 06/24 | 12/24 | | |
Quinones, Tammy |
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension |
|
|
| Recruiting | 3 | 234 | US | Clofazimine Inhalation Suspension, MNKD-101, Placebo | Mannkind Corporation | MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous | 08/26 | 12/28 | | |
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study |
|
|
| Active, not recruiting | 2 | 395 | US | MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo | University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI) | Asthma | 12/24 | 12/24 | | |
NCT05689983: Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers |
|
|
| Recruiting | 1/2 | 40 | US | Maintenance ICS and Symptom Driven SABA, Symptom-driven budesonide/formoterol combination | Washington University School of Medicine, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS) | Asthma in Children, Nonadherence, Medication | 12/24 | 12/24 | | |
NCT05111262: Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers |
|
|
| Recruiting | 1/2 | 60 | US | Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA | Washington University School of Medicine, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS) | Asthma, Nonadherence, Medication | 01/25 | 01/25 | | |
Dunham, Steven |
| Recruiting | 2 | 116 | Europe, US | Inebilizumab, UPLIZNA, Placebo | University of Utah | Autoimmune Encephalitis, Encephalitis | 10/25 | 08/26 | | |
Kolmar, Amanda |
| Recruiting | 2/3 | 258 | US | Enoxaparin, Lovenox, Clexane | Yale University, Children's Hospital Colorado, Children's Hospital of Philadelphia, BJC HealthCare, Medical College of Wisconsin, Children's of Alabama, Golisano Children's Hospital, Maria Fareri Children's Hospital, Nationwide Children's Hospital, New York Presbyterian Hospital, Penn State University, University of Iowa, Johns Hopkins All Children's Hospital, University of Oklahoma, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Children's Hospital of Illinois OSF Saint Francis Medical Center, Hassenfeld Children's Hospital | Deep Venous Thrombosis | 04/26 | 07/26 | | |
| Recruiting | N/A | 228 | Canada, US, RoW | Red blood cell transfusion | Boston Children's Hospital | Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple | 10/24 | 12/25 | | |
Birke, Angela |
VNS-AIS, NCT05390580: Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct |
|
|
| Recruiting | N/A | 80 | US | transcutaneous auricular vagal nerve stimulation, Sham transcutaneous vagal nerve stimulation | Washington University School of Medicine | Acute Ischemic Stroke | 06/24 | 12/24 | | |
Rae, Lindsay |
| Recruiting | 1/2 | 413 | Europe, Canada, US, RoW | revumenib, SNDX-5613, cobicistat | Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | 12/27 | 12/27 | | |
|
|
|
|
|
|
|
|
|